Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse Events

This cohort study evaluates morbidity and mortality outcomes associated with dupilumab treatment in patients with cutaneous immune-related adverse events.

Corresponding Author: Nicholas Gulati, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 E 98th St, 5th Floor, New York, NY 10029 (nicholas.gulati@mssm.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.